EGFR and cancer: Although HER3 expression has been observed in various nonmalignant tissues, similar to other members of the EGFR family (HER1 and HER2), which have different approved treatments for different types of cancer, early clinical trials with agents targeting HER3 have shown a favorable toxicity profile (1), indicating the safety of these HER3 treatments.